Figure 3.

Effects of regorafenib, M‐2, and M‐5 on the growth of human xenografts in mice. Data show relative tumor volume in mice bearing xenografts of (A) human breast cancer cell line MDA‐MB‐231 (KRAS^G13D, BRAF^G464V) and (B) human CRC cell line HT‐29 (BRAF^V600E) following oral administration of 10 mg/kg/day of regorafenib, M‐2, or M‐5 for 27 days, starting at Day 13 or Day 11, respectively, after tumor inoculation (palpable tumor size; n = 8; *P < 0.05 for regorafenib versus vehicle; ^† P < 0.05 for M‐2 versus vehicle; ^‡ P < 0.05 for M‐5 versus vehicle)